AR041061A1 - Uso de la eritropoyetina en pacientes con diabetes - Google Patents
Uso de la eritropoyetina en pacientes con diabetesInfo
- Publication number
- AR041061A1 AR041061A1 ARP030103092A ARP030103092A AR041061A1 AR 041061 A1 AR041061 A1 AR 041061A1 AR P030103092 A ARP030103092 A AR P030103092A AR P030103092 A ARP030103092 A AR P030103092A AR 041061 A1 AR041061 A1 AR 041061A1
- Authority
- AR
- Argentina
- Prior art keywords
- erythropoietin
- conjugate
- protein
- erythropoietin protein
- kilodaltons
- Prior art date
Links
- 206010012601 diabetes mellitus Diseases 0.000 title abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 5
- 108090000394 Erythropoietin Proteins 0.000 abstract 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 101000987586 Homo sapiens Eosinophil peroxidase Proteins 0.000 abstract 2
- 101000920686 Homo sapiens Erythropoietin Proteins 0.000 abstract 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 125000003277 amino group Chemical group 0.000 abstract 2
- 230000013595 glycosylation Effects 0.000 abstract 2
- 238000006206 glycosylation reaction Methods 0.000 abstract 2
- 102000044890 human EPO Human genes 0.000 abstract 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 230000008707 rearrangement Effects 0.000 abstract 1
- 210000001995 reticulocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Uso de la eritropoyetina para el tratamiento de las perturbaciones de la distribución del hierro en pacientes con diabetes. Reivindicación 10: El uso de acuerdo con la reivindicación 9, en el cual la proteína eritropoyetina es un conjugado, dicho conjugado comprende una proteína eritropoyetina que tiene por lo menos un grupo amino libre y tiene una actividad biológica in vivo de hacer que las células de la médula ósea aumenten la producción de reticulocitos y glóbulos rojos y se selecciona del grupo formado por la eritropoyetina humana y sus análogos que tienen una secuencia de la eritropoyetina humana modificada por el agregado de desde 1 hasta 6 sitios de glicosilación o un reordenamiento de por lo menos un sitio de glicosilación; dicha proteína eritropoyetina está ligada en forma covalente a grupos n poli (etilenglicol) de la fórmula -CO-(CH2)x-(OCH2CH2)m-OR o con el -CO de cada grupo poli (etilenglicol) formando un enlace de amida con uno de dichos grupos amino; en la cual R es alquilo inferior; x es 2 ó 3; m es desde aproximadamente 450 hasta aproximadamente 900; n es desde 1 hasta 3; y n y m se eligen de modo tal que el peso molecular del conjugado menos la proteína eritropoyetina es desde 20 Kilodaltons hasta 100 Kilodaltons.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02019100 | 2002-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR041061A1 true AR041061A1 (es) | 2005-04-27 |
Family
ID=31970265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030103092A AR041061A1 (es) | 2002-08-29 | 2003-08-27 | Uso de la eritropoyetina en pacientes con diabetes |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7459435B2 (es) |
| EP (1) | EP1536823B1 (es) |
| JP (1) | JP5128048B2 (es) |
| KR (1) | KR20050057054A (es) |
| CN (1) | CN1311866C (es) |
| AR (1) | AR041061A1 (es) |
| AT (1) | ATE510556T1 (es) |
| AU (1) | AU2003251713B2 (es) |
| BR (1) | BRPI0313792B8 (es) |
| CA (1) | CA2496581C (es) |
| ES (1) | ES2364651T3 (es) |
| MX (1) | MXPA05002067A (es) |
| PL (1) | PL209699B1 (es) |
| RU (1) | RU2305554C2 (es) |
| WO (1) | WO2004019972A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1696947T1 (sl) | 2003-12-19 | 2014-05-30 | F. Hoffmann-La Roche Ag | Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih |
| KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| WO2006061853A2 (en) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Novel erythropoietic compounds and a process for producing erythropoietic compounds |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| WO2007108505A1 (ja) * | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| AU2013250711A1 (en) | 2012-04-19 | 2014-11-27 | Opko Biologics Ltd. | Long-acting oxyntomodulin variants and methods of producing same |
| KR102341581B1 (ko) | 2012-11-20 | 2021-12-21 | 옵코 바이오로직스 리미티드 | 생식샘자극 호르몬 카복시 말단 펩타이드들과 부착하여 폴리펩타이드들의 유체역학적 부피를 증가시키는 방법 |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| PH12021552108A1 (en) | 2014-12-10 | 2022-05-11 | Opko Biologics Ltd | Methods of producing long acting ctp-modified growth hormone polypeptides |
| CN113289009B (zh) | 2015-06-19 | 2025-05-02 | Opko生物科学有限公司 | 长效凝固因子及其产生方法 |
| SG10202100189WA (en) | 2016-07-11 | 2021-02-25 | Opko Biologics Ltd | Long-acting coagulation factor vii and methods of producing same |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| JP2858752B2 (ja) | 1987-04-10 | 1999-02-17 | オーソ・フアーマシユーチカル・コーポレーシヨン | 正常な哺乳動物のヘマトクリツト値の増大方法 |
| FR2646438B1 (fr) * | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
| SG122763A1 (en) | 1989-11-06 | 2006-06-29 | Cell Genesys Inc | Production of proteins using homologous recombination |
| EP0505500B1 (en) | 1989-12-22 | 1997-07-30 | Applied Research Systems Ars Holding N.V. | Endogenous gene expression modification with regulatory element by way of homologous recombination |
| US5272071A (en) * | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9001987D0 (en) * | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| US5324650A (en) * | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| PT101031B (pt) * | 1991-11-05 | 2002-07-31 | Transkaryotic Therapies Inc | Processo para o fornecimento de proteinas por terapia genetica |
| US5733761A (en) * | 1991-11-05 | 1998-03-31 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| ZA946122B (en) | 1993-08-17 | 1995-03-20 | Amgen Inc | Erythropoietin analogs |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| RU2089214C1 (ru) * | 1994-01-06 | 1997-09-10 | Научно-исследовательский центр Санкт-Петербургского медицинского института им.акад.И.П.Павлова | Средство для снижения патологической проницаемости сосудов к белкам |
| US5672662A (en) * | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| DE69800640T2 (de) | 1997-01-29 | 2001-07-05 | Polymasc Pharmaceuticals Plc, London | Pegylationsverfahren |
| IL131959A0 (en) | 1997-03-18 | 2001-03-19 | Roche Diagnostics Gmbh | Pharmaceutical combined preparations containing erythropoietin and iron preparations |
| EP0885613A1 (de) * | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| DE19734293A1 (de) * | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| CN1572320A (zh) * | 1999-05-11 | 2005-02-02 | 奥索－麦克尼尔药物公司 | 利用药代动力学和药效模型进行红细胞生成素给药的方法 |
| JO2291B1 (en) | 1999-07-02 | 2005-09-12 | اف . هوفمان لاروش ايه جي | Erythropoietin derivatives |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| MXPA02011303A (es) | 2000-05-15 | 2003-04-25 | Hoffmann La Roche | Nueva composicion farmaceutica. |
| US20020065214A1 (en) * | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| JP4656814B2 (ja) * | 2000-12-20 | 2011-03-23 | エフ．ホフマン−ラ ロシュ アーゲー | エリスロポエチンコンジュゲート |
| ES2297011T3 (es) | 2001-09-14 | 2008-05-01 | F. Hoffmann-La Roche Ag | Diagnostico diferencial de los trastornos del metabolismo del hierro por medio de tres parametros independientes y recomendaciones para el tratamiento de estos trastornos del metabolismo del hierro. |
-
2003
- 2003-08-04 US US10/634,477 patent/US7459435B2/en not_active Expired - Lifetime
- 2003-08-20 AU AU2003251713A patent/AU2003251713B2/en not_active Expired
- 2003-08-20 RU RU2005108976/15A patent/RU2305554C2/ru active
- 2003-08-20 KR KR1020057003501A patent/KR20050057054A/ko not_active Ceased
- 2003-08-20 CN CNB038205459A patent/CN1311866C/zh not_active Expired - Lifetime
- 2003-08-20 BR BRPI0313792A patent/BRPI0313792B8/pt not_active IP Right Cessation
- 2003-08-20 EP EP03790911A patent/EP1536823B1/en not_active Expired - Lifetime
- 2003-08-20 JP JP2004532098A patent/JP5128048B2/ja not_active Expired - Lifetime
- 2003-08-20 AT AT03790911T patent/ATE510556T1/de active
- 2003-08-20 CA CA2496581A patent/CA2496581C/en not_active Expired - Lifetime
- 2003-08-20 MX MXPA05002067A patent/MXPA05002067A/es active IP Right Grant
- 2003-08-20 PL PL375784A patent/PL209699B1/pl unknown
- 2003-08-20 WO PCT/EP2003/009194 patent/WO2004019972A1/en not_active Ceased
- 2003-08-20 ES ES03790911T patent/ES2364651T3/es not_active Expired - Lifetime
- 2003-08-27 AR ARP030103092A patent/AR041061A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| BR0313792A (pt) | 2005-07-12 |
| RU2305554C2 (ru) | 2007-09-10 |
| CN1678341A (zh) | 2005-10-05 |
| BRPI0313792B1 (pt) | 2016-10-18 |
| MXPA05002067A (es) | 2005-06-08 |
| ES2364651T3 (es) | 2011-09-08 |
| PL209699B1 (pl) | 2011-10-31 |
| US7459435B2 (en) | 2008-12-02 |
| JP5128048B2 (ja) | 2013-01-23 |
| PL375784A1 (en) | 2005-12-12 |
| US20040110679A1 (en) | 2004-06-10 |
| RU2005108976A (ru) | 2006-01-27 |
| CA2496581C (en) | 2019-09-03 |
| JP2006503821A (ja) | 2006-02-02 |
| KR20050057054A (ko) | 2005-06-16 |
| ATE510556T1 (de) | 2011-06-15 |
| EP1536823A1 (en) | 2005-06-08 |
| AU2003251713B2 (en) | 2006-12-21 |
| WO2004019972A1 (en) | 2004-03-11 |
| CA2496581A1 (en) | 2004-03-11 |
| BRPI0313792B8 (pt) | 2021-05-25 |
| AU2003251713A1 (en) | 2004-03-19 |
| CN1311866C (zh) | 2007-04-25 |
| EP1536823B1 (en) | 2011-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR041061A1 (es) | Uso de la eritropoyetina en pacientes con diabetes | |
| CO5190661A1 (es) | Derivados de la eritropoyetina | |
| AR035407A1 (es) | Conjugados de eritropoyetina, composiciones farmaceuticas que los comprenden, uso de dichos conjugados en la preparacion de medicamentos, proceso para preparar dichos conjugados y glicoproteinas de eritropoyetina | |
| ATE505204T1 (de) | Konjugate von erythropoietin (epo) mit polyethylenglykol (peg) | |
| EA200200755A1 (ru) | Опосредованная рецептором nogo блокада роста аксонов | |
| RU2008145084A (ru) | Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo | |
| BRPI0109494B8 (pt) | muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii | |
| BRPI0416683A (pt) | muteìna de fator de crescimento de fibroblasto de humano 21 (fgf-21), ou um seu peptìdeo biologicamente ativo, polinucleotìdeo, vetor de expressão, célula hospedeira, processo para produzir um polipeptìdeo, composição farmacêutica, método para tratar um paciente, e, uso da muteìna fgf-21 | |
| BRPI0012138B8 (pt) | conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição | |
| BRPI0811320A2 (pt) | Surfactantes reconstituídos com propriedades melhoradas | |
| RU2005119649A (ru) | Новое применение эритропоэтина при сердечных заболеваниях | |
| WO2016130573A3 (en) | Degradable thiol-ene polymers and methods of making thereof | |
| DE69535895D1 (de) | Resorbierbare synthetische proteine zur verwendung in implantaten | |
| WO1994012219A3 (en) | Modified insulin-like growth factors | |
| EE05497B1 (et) | Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha | |
| ATE500847T1 (de) | Pegylierte g-csf-polypeptide und herstellungsverfahren dafür | |
| DE602004028239D1 (de) | Protease, für die protease codierende dna und verfahren zur herstellung der protease | |
| BRPI0515893B8 (pt) | peptídeos da proteína humana de estresse térmico, composição farmacêutica, e, uso do peptídeo e da composição farmacêutica. | |
| TW200727911A (en) | Treatment of neurodegenerative disorders | |
| ATE538806T1 (de) | Peptide mit spezifischem sitz in herzgefässen und verwandte konjugate und verfahren | |
| JO2257B1 (en) | Erythropoietin derivatives | |
| ECSP003557A (es) | Derivados de eritropoyetina | |
| EP3974028A1 (en) | Pharmaceutical composition for joint disease treatment and method for producing same | |
| SE9402332D0 (sv) | Igf-1 | |
| WO2005087809B1 (en) | Peptides from vitronectin and their therapeutic exploitation for osteoblast adhesion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |